Am J Psychiatry 161:343-351, February 2004
© 2004 American Psychiatric Association
Continuous or Intermittent Dosing With Sertraline for Patients With Severe Premenstrual Syndrome or Premenstrual Dysphoric Disorder
Ellen W. Freeman, Ph.D.,
Karl Rickels, M.D.,
Steven J. Sondheimer, M.D.,
Marcia Polansky, Sc.D., and
Sha Xiao, M.S.
OBJECTIVE: The authors compared the efficacy and acceptability of continuous versus intermittent treatment with a selective serotonin reuptake inhibitor in women with severe premenstrual syndrome and determined the effects of postmenstrual symptom severity and depression history as covariates of the treatment response. METHOD: Patients who met symptom criteria and reported impaired functioning after three screening cycles were randomly assigned to three cycles of double-blind, placebo-controlled treatment with continuous (full-cycle dosing) or intermittent (luteal-phase dosing) sertraline. The design was stratified for severity of postmenstrual symptoms and history of major depression. Flexible sertraline dose was 50–100 mg/day. Outcome measures were the Daily Symptom Rating Form score and patient global ratings of functioning. RESULTS: Both sertraline groups improved significantly more than the placebo group as assessed by total premenstrual Daily Symptom Rating Form scores for 3 treatment months. Daily Symptom Rating Form factors that were significantly more improved in the sertraline groups were mood and physical symptoms. Sertraline improvement occurred swiftly in the first month of treatment. Gradual placebo improvement was similar to sertraline in the third month. Subjects with higher postmenstrual symptoms before treatment remained more symptomatic regardless of the dosing regimen. A history of major depression was not associated with treatment response. More sertraline-treated subjects reported improved functioning in the domains of family relationships, social activities, and sexual activity. CONCLUSIONS: Premenstrual dosing does not differ from continuous dosing with sertraline in premenstrual syndrome treatment. Higher levels of postmenstrual symptoms limit treatment response and are important to define in treatment of premenstrual syndrome.
Related Article:
-
In This Issue
Am J Psychiatry 2004 161: A70.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
C. I Jarvis, A. M Lynch, and A. K Morin
Management Strategies for Premenstrual Syndrome/Premenstrual Dysphoric Disorder
Ann. Pharmacother.,
July 1, 2008;
42(7):
967 - 978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. R. Shah, J. B. Jones, J. Aperi, R. Shemtov, A. Karne, and J. Borenstein
Selective Serotonin Reuptake Inhibitors for Premenstrual Syndrome and Premenstrual Dysphoric Disorder: A Meta-Analysis
Obstet. Gynecol.,
May 1, 2008;
111(5):
1175 - 1182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Dhingra, J. L. Magnay, P. M. S. O'Brien, G. Chapman, A. A. Fryer, and K. M. K. Ismail
Serotonin Receptor 1A C(-1019)G Polymorphism Associated With Premenstrual Dysphoric Disorder
Obstet. Gynecol.,
October 1, 2007;
110(4):
788 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Henshaw
PMS: diagnosis, aetiology, assessment and management: REVISITING... PREMENSTRUAL SYNDROME
Advan. Psychiatr. Treat.,
March 1, 2007;
13(2):
139 - 146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Continuous vs. Intermittent Sertraline Dosing for PMS
Journal Watch Psychiatry,
April 22, 2004;
2004(422):
9 - 9.
[Full Text]
|
|
|
|
|
|
|
Sertraline for Severe PMS: Intermittent and Continuous Dosing Are Equally Effective
Journal Watch Women's Health,
March 23, 2004;
2004(323):
3 - 3.
[Full Text]
|
|
|
|
|
|
|
Continuous vs. Intermittent Sertraline Dosing for PMS
Journal Watch (General),
March 9, 2004;
2004(309):
3 - 3.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
